Patient-derived Glioma Organoids Real Time Identification of IDH Mutation, 1p/19q-codeletion and CDKN2A/B Homozygous Deletion with Differential Ion Mobility Spectrometry

Overview

Journal J Neurooncol

Publisher Springer

Date 2024 Nov 22

PMID 39578301

Authors

Ismail Hermelo

Ilkka Haapala

Meri Makela

Dafne Jacome Sanz

Anton Kontunen

Markus Karjalainen

Philipp Muller

Kai Lehtimaki

Matti Nykter

Juhana Frosen

Hannu Haapasalo

Antti Roine

Niku Oksala

Kristiina Nordfors

Antti Vehkaoja

Joonas Haapasalo

Affiliations

Soon will be listed here.

Abstract

Purpose: Extent of brain tumor resection continues to be one of the central decisions taken during standard of care in glioma patients. Here, we aimed to evaluate the most essential molecular factors, such as IDH (isocitrate dehydrogenase) mutation in gliomas classification with patient-derived glioma organoids (PGOs) using differential mobility spectrometry (DMS).

Methods: we prospectively recruited 12 glioma patients, 6 IDH-mutated and 6 IDH wild-type tumors, from which PGOs were generated ex-vivo. Altogether, 320 PGOs DMS spectra were analyzed with a classifier algorithm based on linear discriminant analysis (LDA).

Results: LDA model classification accuracy (CA) obtained between IDH-mutant and IDH wild-type PGOs was 90% (91% sensitivity and 89% specificity). Furthermore, 1p/19q codeletion classification within IDH mutant PGOs reached 98% CA (93% sensitivity and 99% specificity), while CDKN2A/B homozygous loss status had 86% CA (63% sensitivity 93% specificity).

Conclusion: DMS suitability to differentiate IDH-mutated PGOs was thus validated in ex vivo cultured samples, PGOs. Preliminary results regarding 1p/19q codeleted PGOs and CDKN2A/B loss PGOs identification endorse testing in a prospective intraoperative glioma patient cohort. Our results reveal a sample classification set-up that is compatible with real-time intraoperative surgery guidance.

References

Patel T, Bander E, Venn R, Powell T, Cederquist G, Schaefer P . The Role of Extent of Resection in IDH1 Wild-Type or Mutant Low-Grade Gliomas. Neurosurgery. 2017; 82(6):808-814. PMC: 7571505. DOI: 10.1093/neuros/nyx265. View

Reinhardt A, Stichel D, Schrimpf D, Sahm F, Korshunov A, Reuss D . Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathol. 2018; 136(2):273-291. DOI: 10.1007/s00401-018-1837-8. View

Van Hese L, de Vleeschouwer S, Theys T, Rex S, Heeren R, Cuypers E . The diagnostic accuracy of intraoperative differentiation and delineation techniques in brain tumours. Discov Oncol. 2022; 13(1):123. PMC: 9649524. DOI: 10.1007/s12672-022-00585-z. View

Koopmans A, Ober K, Dubbink H, Paridaens D, Naus N, Belunek S . Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions. Invest Ophthalmol Vis Sci. 2014; 55(9):6024-30. DOI: 10.1167/iovs.14-14901. View

Xiong G, Deng L, Zhu J, Rychahou P, Xu R . Prolyl-4-hydroxylase α subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition. BMC Cancer. 2014; 14:1. PMC: 3880410. DOI: 10.1186/1471-2407-14-1. View

Fallon K, Palmer C, Roth K, Nabors L, Wang W, Carpenter M . Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol. 2004; 63(4):314-22. DOI: 10.1093/jnen/63.4.314. View

Beiko J, Suki D, Hess K, Fox B, Cheung V, Cabral M . IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol. 2013; 16(1):81-91. PMC: 3870823. DOI: 10.1093/neuonc/not159. View

Louis D, Perry A, Wesseling P, Brat D, Cree I, Figarella-Branger D . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8):1231-1251. PMC: 8328013. DOI: 10.1093/neuonc/noab106. View

Hua W, Zhang W, Brown H, Wu J, Fang X, Shahi M . Rapid detection of IDH mutations in gliomas by intraoperative mass spectrometry. Proc Natl Acad Sci U S A. 2024; 121(23):e2318843121. PMC: 11161794. DOI: 10.1073/pnas.2318843121. View

Tsuriel S, Hannes V, Hasona A, Raz M, Hershkovitz D . Digital PCR-Based Method for Detecting CDKN2A Loss in Brain Tumours. Mol Diagn Ther. 2022; 26(6):689-698. DOI: 10.1007/s40291-022-00610-5. View

10.

Xie Y, Bergstrom T, Jiang Y, Johansson P, Marinescu V, Lindberg N . The Human Glioblastoma Cell Culture Resource: Validated Cell Models Representing All Molecular Subtypes. EBioMedicine. 2015; 2(10):1351-63. PMC: 4634360. DOI: 10.1016/j.ebiom.2015.08.026. View

11.

Wijnenga M, French P, Dubbink H, Dinjens W, Atmodimedjo P, Kros J . The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro Oncol. 2017; 20(1):103-112. PMC: 5761503. DOI: 10.1093/neuonc/nox176. View

12.

Jarvela S, Parkkila S, Bragge H, Kahkonen M, Parkkila A, Soini Y . Carbonic anhydrase IX in oligodendroglial brain tumors. BMC Cancer. 2008; 8:1. PMC: 2245965. DOI: 10.1186/1471-2407-8-1. View

13.

Chai R, Zhang K, Chang Y, Wu F, Liu Y, Zhao Z . Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma. Carcinogenesis. 2019; 40(10):1229-1239. DOI: 10.1093/carcin/bgz102. View

14.

Vermeulen C, Pages-Gallego M, Kester L, Kranendonk M, Wesseling P, Verburg N . Ultra-fast deep-learned CNS tumour classification during surgery. Nature. 2023; 622(7984):842-849. PMC: 10600004. DOI: 10.1038/s41586-023-06615-2. View

15.

Hubert C, Rivera M, Spangler L, Wu Q, Mack S, Prager B . A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found In Vivo. Cancer Res. 2016; 76(8):2465-77. PMC: 4873351. DOI: 10.1158/0008-5472.CAN-15-2402. View

16.

Kawaguchi T, Sonoda Y, Shibahara I, Saito R, Kanamori M, Kumabe T . Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion. J Neurooncol. 2016; 129(3):505-514. DOI: 10.1007/s11060-016-2201-2. View

17.

Huang L . Impact of Homozygous Deletion on the Prognosis and Biology of IDH-Mutant Glioma. Biomedicines. 2022; 10(2). PMC: 8869746. DOI: 10.3390/biomedicines10020246. View

18.

Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn J, Minniti G . EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2020; 18(3):170-186. PMC: 7904519. DOI: 10.1038/s41571-020-00447-z. View

19.

Mellinghoff I, van den Bent M, Blumenthal D, Touat M, Peters K, Clarke J . Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med. 2023; 389(7):589-601. PMC: 11445763. DOI: 10.1056/NEJMoa2304194. View